Measured Wealth Private Client Group LLC Acquires 14,449 Shares of Organon & Co. (NYSE:OGN)

Measured Wealth Private Client Group LLC grew its holdings in shares of Organon & Co. (NYSE:OGN) by 68.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 35,586 shares of the company’s stock after acquiring an additional 14,449 shares during the quarter. Measured Wealth Private Client Group LLC’s holdings in Organon & Co. were worth $531,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of OGN. Prospera Private Wealth LLC bought a new stake in Organon & Co. during the third quarter valued at approximately $25,000. Horizon Bancorp Inc. IN raised its position in shares of Organon & Co. by 2,401.5% during the 4th quarter. Horizon Bancorp Inc. IN now owns 1,651 shares of the company’s stock valued at $25,000 after buying an additional 1,585 shares in the last quarter. Abich Financial Wealth Management LLC lifted its holdings in shares of Organon & Co. by 5,646.3% during the 3rd quarter. Abich Financial Wealth Management LLC now owns 2,356 shares of the company’s stock worth $45,000 after acquiring an additional 2,315 shares during the last quarter. Trust Co. of Vermont grew its position in Organon & Co. by 109.4% in the third quarter. Trust Co. of Vermont now owns 2,626 shares of the company’s stock worth $50,000 after acquiring an additional 1,372 shares in the last quarter. Finally, MassMutual Private Wealth & Trust FSB increased its stake in Organon & Co. by 32.4% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 2,749 shares of the company’s stock valued at $41,000 after acquiring an additional 672 shares during the last quarter. Hedge funds and other institutional investors own 77.43% of the company’s stock.

Analyst Ratings Changes

Separately, TD Cowen raised Organon & Co. to a “hold” rating in a research note on Wednesday, January 15th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $21.33.

Organon & Co. Trading Down 2.7 %

OGN stock opened at $14.88 on Friday. The company has a market capitalization of $3.83 billion, a PE ratio of 2.95, a price-to-earnings-growth ratio of 0.87 and a beta of 0.76. The company has a debt-to-equity ratio of 17.73, a quick ratio of 1.21 and a current ratio of 1.70. Organon & Co. has a one year low of $13.87 and a one year high of $23.10. The company’s 50 day moving average price is $15.39 and its two-hundred day moving average price is $17.77.

Organon & Co. Company Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.